Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer

BJU International

Volumn 102, Issue 9B, 2008, Pages 1339-1344

  Milowsky, Matthew I ^a,b   Stadler, Walter M ^c   Bajorin, Dean F ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Adjuvant; Bladder cancer; Chemotherapy; Cystectomy; Neoadjuvant; Transitional cell carcinoma; Urothelial cancer

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FOLINIC ACID; GEMCITABINE; METHOTREXATE; PACLITAXEL; SUNITINIB; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BLADDER CANCER; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CYSTECTOMY; HUMAN; LYMPH NODE DISSECTION; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PATIENT CARE; PELVIS LYMPH NODE; PRIORITY JOURNAL; REVIEW; RISK; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CLINICAL TRIALS AS TOPIC; CYSTECTOMY; DOXORUBICIN; HUMANS; METHOTREXATE; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 54049111801     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07980.x     Document Type: Review

References (46)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin 2007 57 : 43 66
2. Herr HW, Bochner BH, Dalbagni G et al. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 2002 167 : 1295 8
3. Kassouf W, Leibovici D, Munsell MF et al. Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. J Urol 2006 176 : 53 7
4. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001 19 : 666 75
5. von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005 23 : 4602 8
6. Millikan R, Dinney C, Swanson D et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 2001 19 : 4005 13
7. Donat SM, Shabsigh A, Savage C et al. Protential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol 2008 (Epub ahead of print)
8. Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer. J Urol 2005 174 : 14 20
9. Herr HW, Donat SM, Bajorin DF. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 2001 165 : 811 4
10. Loehrer PJ Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992 10 : 1066 73
11. Logothetis CJ, Dexeus F, Sella A et al. A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastatic urothelial tumors. J Clin Oncol 1990 8 : 1050 5
12. Wallace DM, Raghavan D, Kelly KA et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 1991 67 : 608 15
13. Martinez-Pineiro JA, Gonzalez Martin M, Arocena F et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 1995 153 : 964 73
14. Malmstrom PU, Rintala E, Wahlqvist R et al. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 1996 155 : 1903 6
15. Sherif A, Rintala E, Mestad O et al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer - Nordic cystectomy trial 2. Scand J Urol Nephrol 2002 36 : 419 25
16. Sengelov L, von der Maase H, Lundbeck F et al. Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours. Acta Oncol 2002 41 : 447 56
17. Shipley WU, Winter KA, Kaufman DS et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998 16 : 3576 83
18. International Collaboration of Trialists. Neoadjuvant cisplatin methotrexate and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 1999 354 : 533 40
19. Hall RR. Updated results of a randomized trial of neoadjuvant cisplatin (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer. Proc Am Soc Clin Oncol 2002 21 : 178a, Abstract 710
20. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003 349 : 859 66
21. Anonymous. Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev 2005 2): CD005246
22. Dash AJ, Pettus BH, Bochner G et al. Efficacy of neo-adjuvant gemcitabine plus cisplatin (GC) in muscle-invasive urothelial cancer. Proc Am Soc Clin Oncol 2007 25 : 254s, Abstract 5077
23. Dutta SC, Smith JA Shappell SB et al. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 2001 166 : 490 3
24. Miladi M, Peyromaure M, Zerbib M et al. The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol 2003 43 : 241 5
25. Studer U, Bacchi M, Biederman C et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 1994 152 : 81 4
26. Skinner DG, Daniels JR, Russell CA et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991 145 : 459 64
27. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996 155 : 495 9
28. Stockle M, Meyenburg W, Wellek S et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992 148 : 302 6
29. Stockle M, Meyenburg W, Wellek S et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 1995 153 : 47 52
30. Stockle M, Wellek S, Meyenburg W et al. Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement. Urology 1996 48 : 868 75
31. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Eur Urol 2005 48 : 189 99
32. Rosenberg JE. Current status of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Expert Rev Anticancer Ther 2007 7 : 1729 36
33. David KA, Milowsky MI, Ritchey J et al. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998-2003: a report from the National Cancer Data Base. J Urol 2007 178 : 451 4
34. Eigl BJ, Ma BJ. Do clinical practice guidelines (CPG) change clinical practice? An analysis of CPG impact on referral and treatment patterns for neoadjuvant chemotherapy in bladder cancer. Proc Genitourin Cancers Symp 2008 240. Abstract 295
35. Dogliotti L, Carteni G, Siena S et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 2007 52 : 134 41
36. Takata R, Katagiri T, Kanehira M et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005 11 : 2625 36
37. Bellmunt J, Paz-Ares L, Cuello M et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007 18 : 522 8
38. Dickinson AJ, Fox SB, Persad RA et al. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 1994 74 : 762 6
39. Jaeger TM, Weidner N, Chew K et al. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 1995 154 : 69 71
40. Bochner BH, Cote RJ, Weidner N et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995 87 : 1603 12
41. Brown LF, Berse B, Jackman RW et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993 143 : 1255 62
42. Chopin DK, Caruelle JP, Colombel M et al. Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine. J Urol 1993 150 : 1126 30
43. Nguyen M, Watanabe H, Budson AE et al. Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst 1993 85 : 241 2
44. Inoue K, Slaton JW, Davis DW et al. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res 2000 6 : 2635 43
45. Inoue K, Chikazawa M, Fukata S et al. Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma. Clin Cancer Res 2003 9 : 886 99
46. Inoue K, Chikazawa M, Fukata S et al. Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder. Clin Cancer Res 2002 8 : 2389 98